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METHODOLOGY Open Access
Longitudinal multi-centre brain imaging
studies: guidelines and practical tips for
accurate and reproducible imaging
endpoints and data sharing
Stewart J. Wiseman1,2,3* , Rozanna Meijboom1,2, Maria del C. Valdés Hernández1,2, Cyril Pernet1, Eleni Sakka1,
Dominic Job1, Adam D. Waldman1 and Joanna M. Wardlaw1,2
Abstract
Background: Research involving brain imaging is important for understanding common brain diseases. Study
endpoints can include features and measures derived from imaging modalities, providing a benchmark against
which other phenotypical data can be assessed. In trials, imaging data provide objective evidence of beneficial and
adverse outcomes. Multi-centre studies increase generalisability and statistical power. However, there is a lack of
practical guidelines for the set-up and conduct of large neuroimaging studies.
Methods: We address this deficit by describing aspects of study design and other essential practical considerations
that will help researchers avoid common pitfalls and data loss.
Results: The recommendations are grouped into seven categories: (1) planning, (2) defining the imaging endpoints,
developing an imaging manual and managing the workflow, (3) performing a dummy run and testing the analysis
methods, (4) acquiring the scans, (5) anonymising and transferring the data, (6) monitoring quality, and (7) using
structured data and sharing data.
Conclusions: Implementing these steps will lead to valuable and usable data and help to avoid imaging data wastage.
Keywords: Longitudinal, Multi-centre, Magnetic resonance imaging, Study design, Data sharing, Guidelines, Big data
Background
Research involving brain imaging contributes to our
understanding of common brain diseases such as stroke
[1], dementia [2], multiple sclerosis [3] and brain tu-
mours [4]. Imaging endpoints are used in clinical trials
[5, 6] to provide objective evidence of beneficial and
adverse outcomes, and imaging-derived features have
become phenotypes in their own right. Aims will differ
across studies, and imaging can be used to drive main
endpoints but also as an exploratory tool that contrib-
utes to our understanding of disease mechanisms. Lon-
gitudinal multi-centre studies, in which patients from
different centres are imaged repeatedly over time, allow
greater numbers of subjects to be recruited, and can
generate insights into disease progression and out-
comes that are not available in cross-sectional studies.
Such studies are, however, expensive and complex to
organise, and require careful co-ordination and manage-
ment to optimise the answering of research hypotheses.
Large sample sizes help reduce uncertainty and in-
crease reliability in clinical decisions and clinical practice
strategies, which are then informed by research evi-
dence. Multi-centre imaging studies are one response to
the increasing demand for more data. Generalisability
and statistical power are enhanced with a larger study
sample size. Such studies promote collaborations across
institutions and countries, and experts worldwide will
have access to the large data sets and can combine their
group expertise [7] (e.g. http://enigma.ini.usc.edu/).
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It is important to ensure that appropriate technologies
and strategies are used to manage the large amounts of
data generated: some of the challenges include captur-
ing, storing, analysing, searching, sharing, transferring,
visualising, querying, protecting and updating data – all
in addition to maintaining patient confidentiality and ad-
hering to good clinical practice.
A carefully conducted longitudinal or multi-centre study
will yield valuable data, which are essential for addressing
the study’s research questions. It is unethical to conduct a
study if there is a high risk of data loss or misuse, or other
problems that restrict the ability to answer the research
question. Not only are high-quality data essential for an-
swering the predefined research question, these data could
also help other scientists from all over the world answer
other questions. Data sharing and open science are im-
portant contemporary topics in medical research. The
International Committee of Medical Journal Editors, UK
Research and Innovation (https://www.ukri.org/funding/
information-for-award-holders/open-access/), and some
of the charities now mandate data sharing [8]. This in-
cludes the computer code [9] (image processing pipelines)
that generates the research output from images. The Lancet
[10] is promoting improved management and sharing of
research data as these reduce ‘research wastage’ and reward
scientific diligence; see the REWARD Statement, http://
www.thelancet.com/campaigns/efficiency/statement).
Guidelines for designing [11], recruiting to [12], organis-
ing [13] and performing quality assurance [14, 15] in
multi-centre trials have been published. Brain imaging pro-
tocols for large multi-centre imaging data collections also
exist, e.g. UK Biobank [16, 17], Alzheimer’s Disease Neuro-
imaging Initiative (http://adni.loni.usc.edu/methods/docu-
ments/mri-protocols/) and the Lothian Birth Cohort [18],
and data standards for clinical research are supported by
the Equator Network (http://www.equator-network.org/)
and the National Institute of Neurological Disorders and
Stroke (https://www.commondataelements.ninds.nih.gov/).
Additionally, much emphasis has been placed on data
sharing after primary studies are completed. A detailed
report (http://www.humanbrainmapping.org/files/2016/
COBIDASreport.pdf ) – summarised in Nature Neuro-
science [19] – by the Organization for Human Brain
Mapping and its Committee on Best Practice in Data
Analysis and Sharing (http://www.humanbrainmappin-
g.org/cobidas) includes over 100 items to help plan,
execute, report and share neuroimaging research. Rec-
ommendations already exist for multi-centre functional
magnetic resonance imaging (fMRI) studies [20] that
have specific guidance, such as how to organise meta-
data [21] from task-based fMRI. Methodological issues
for guarding against false positives and overstating ef-
fect sizes in neurogenetic studies have been discussed
[22]. However, concrete practical advice, in an easily
digestible format, that guides the setting up of a longi-
tudinal multi-centre structural neuroimaging study is
lacking.
Here, we describe considerations that, in our experi-
ence, are necessary when designing and starting a lon-
gitudinal multi-centre brain imaging study. Figure 1
(adapted from Chung et al. [13]) shows where amongst
the current recommendations and guidelines for con-
ducting studies this work sits. This guideline contains
specific technical examples and is illustrated with some
common pitfalls that can threaten a study if not moni-
tored and rectified when identified. Conducting studies
appropriately will help achieve correct answers, avoid
wastage of money and data, and ultimately improve pa-
tient care. A flow diagram of the experience-based rec-
ommended systematic approach we propose is
illustrated in Fig. 2. Note that imaging should be con-
sidered at all stages in the design of a study, including
the literature search, although we focus here on the
more downstream aspects of study implementation
since, in our experience, this is a neglected area.
Results and discussion
The key points explained
Planning phase
The early involvement of imaging personnel with rele-
vant expertise cannot be overemphasised, since it will
generate insights that can be fed into the main study
protocol. These individuals are best placed to comment
on what type of imaging will best answer the research
question, for instance: which modality, if MRI the field
strength and sequences, the image analysis methods,
and who will carry out the analyses. Experts from the
following fields bring a wealth of divergent knowledge:
 Neuroradiologists for general advice and insight, and
for reading the images, reporting on incidental findings
and advising on which sequences are best suited to
answer the research question
 Radiographers for practical insights, e.g. a scan
protocol with 25 min on-table will require a longer
booking slot in a cohort of multiple sclerosis patients
with severe movement difficulties
 Medical physicists to optimise technical parameters,
e.g. to lower the specific absorption rate in MRI
sequences with high flip angles or short repetition
time, which is particularly relevant at 3 tesla, and for
advice on protection from ionising radiation
 Radiochemists for advice on tracers for positron
emission tomography (PET) and other radionuclide
studies
 Image analysts to help specify the technical
parameters to optimise efficient information
extraction. For example, isotropic voxels can be used
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Fig. 1 Where this guideline sits in the literature (adapted from Chung et al. [13]). IRAS Integrated Research Application System, IRB institutional review board
Fig. 2 Summary of key points to consider in setting up a multi-centre brain imaging research study. BIDS brain imaging data structure, CT computed
tomography, MRI magnetic resonance imaging, PET positron emission tomography, QC quality control
Wiseman et al. Trials           (2019) 20:21 Page 3 of 10
to reconstruct an image with the same in-plane
resolution in different orientations but can bias
diffusion estimates [23]; the planned analysis should
guide the acquisition parameters
 Data managers for anonymising, storing accurately
and robustly, and versioning metadata and moving
large volumes of imaging data, which can be
expensive and require specialists with specific
knowledge of hardware and software
 Facilities managers to help cost and resource the
project adequately, and to deal with unexpected
costs, e.g. staff illness or equipment failure
The imaging manual and related systems of work
Writing the main study protocol correctly, and subse-
quently, an ethics application will be possible only after
the planning and consultation phase. An imaging proto-
col should also be written and tested. It should include:
a. Contact details (principal investigator and imaging staff)
b. Brief introduction and study rationale
c. Aims and hypotheses, clearly described
d. Imaging endpoints and outputs—be specific, e.g.
total brain tissue volume change over 1 year; white
matter hyperintensity burden using the Fazekas
scale, etc. This can be enhanced later based on new
research findings, but at the minimum a framework
that ensures the basic output needed to answer the
research questions should be in place from the
beginning
e. Image acquisition including explicit acquisition
parameters and radiographer instructions (e.g. “Do
not angle acquisition direction on diffusion tensor
imaging, but instead plan a straight axial with no
in-plane rotation”); pictures can be helpful
f. Anonymisation procedure, file naming conventions,
upload procedure for Digital Imaging and
Communications in Medicine files (DICOM)
g. Quality control (QC) procedure for inter- and
intra-site reliability and reproducibility
h. Details of the image management system (see below)
i. Appendices (further detailed technical parameters,
log sheets to record notes specific to a scan session,
e.g. ‘patient anxious’ or ‘only first two sequences
acquired’)
Once the imaging manual is live, it should not be al-
tered. A change made after the study is underway will
increase the noise in the data, make the analysis ineffi-
cient and potentially reduce the sample size if images
cannot be used. However, it is also important to be
pragmatic. The protocol should be altered if there is an
essential improvement that is beneficial to the study.
As an example, the authors implemented a new version
of an imaging manual for a large multi-centre study to
change the T2-weighted scan to a dual echo T2. This
change permitted the generation of a proton density-
weighted image, which allowed for improved brain
extraction from the images. The same protocol (se-
quences and parameters) used at baseline should be
used at the follow-up. Also consider:
 Incidental findings [24] and how they will be handled
[25, 26], e.g. if studying multiple sclerosis, there
should be a mechanism to deal with a suspected
brain tumour. A cogent policy for management of
incidental findings is now mandated in UK
Research Ethics applications and by the Medical
Research Council and Wellcome Trust, both major
funders of human imaging research.
 If available, follow disease-specific agreed-upon
recommendations that guide choice of scan
sequences (see the example of a small vessel disease
in [1]) and where relevant new methods of analysis
(but ensure the proposed method is relevant to your
population and research question and has been
validated for your scans and patients).
 Harmonisation of sequences across sites: different
sites might conduct imaging on different
manufacturer’s hardware, and even the same scanner
at two different sites might be running different
software versions. It is important to investigate these
issues and assess any impact on the proposed imaging
outcome measures.
 A plan to cope with unforeseen circumstances, such
as scanner upgrades.
 The availability of head coils should also be considered.
 In MRI studies, consider safety contra-indications
(e.g. a cardiac pacemaker) and subject heating
(specific absorption rate). Consider the radiation
dose in studies using computed tomography, PET or
any radionuclides.
 Consider how the image data and related
phenotypes will be stored and managed. The
recommendations presented in this paper require an
image management system that will handle scan
transfers, data housekeeping, systematic reviews of
the data and data queries. Involving database experts
that understand database schemas is the most robust
approach. The upfront cost of developing such a
system will be repaid in efficiency gains. Storage of,
and linking to, other study data including genetic and
clinical variables is a further step in integrating all
study data. Combining neuroimaging data with other
study variables, particularly if they include full
genome sequencing, will result in massive datasets
[27]. Figure 3 covers some elements of an image
management system, including:
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◦ a record of the scan datasets received (when
received, which centre sent the data and key
variables extracted from the DICOM headers, such
as scan date)
◦ notes from the QC process (e.g. pass or fail, and
if the scan failed, a reason)
◦ links to where the raw data are stored, notes on
how it was processed (including the software used
and version numbers, problems encountered and
who did the processing), links to where the
processed output is stored
An image management system is important. The 3rd
International Stroke Trial investigated alteplase in acute
ischaemic stroke and used brain imaging as a critical
component of the diagnosis and safety outcome assess-
ments. Our centre coordinated imaging from 3035 pa-
tients in 156 centres in 12 countries from 2000 to 2012,
yielding a total of over 7000 scans. In this trial, which
used an efficient image management system, missing
scans were queried in 4.2% of patients (only 17 of these
(0.5%) were missing in the end) and 2.4% of scans had
imaging issues rendering them unsuitable for reading.
Either a commercial or open-source image manage-
ment system is worth investigating. One example is the
Hive database system (theHiveDB) [28], although we
have not used it and are unable to comment on its util-
ity. Researchers should attempt to minimise scan losses
(by considering this guideline) but also allow for a
percentage of losses in power calculations, just as for
subject loss to follow-up.
Dummy run test scan
Testing the imaging protocol on a healthy volunteer or
patient with the disease of interest is essential. Each site
should do this and upload the dummy scan to the host-
ing facility to verify all aspects of the study are as ex-
pected (image quality, anonymisation, and upload and
transfer procedures). On-study scanning should start
only after acceptance. The analysis pipeline should also
be tested at an early stage.
Acquire
High quality and consistent scans are essential for success-
ful scientific studies. In some studies, images are assessed
by radiologists or trained observers, who give their opin-
ion on, for example, disease status or detailed visual scor-
ing, and it is important that image quality is sufficient for
such reads. Likewise, images are often processed using au-
tomated or semi-automated algorithms that require con-
sistent contrast, resolution and subject positioning, which
are dependent upon fixed acquisition parameters such as
acquisition orientation, field of view, and matrix, to min-
imise between-scan noise.
Pitfalls Some subjects find it difficult to tolerate the
scan session. Restless patients can affect scan quality,
particularly for sequences like MRI fluid-attenuated
Fig. 3 Image management system, including example screenshots of the user interface. DICOM Digital Imaging and Communications in Medicine (file type)
Wiseman et al. Trials           (2019) 20:21 Page 5 of 10
inversion recovery (FLAIR) or susceptibility-weighted im-
aging, which are more sensitive to movement. Figure 4 has
examples of some scan errors. Figure 4(a) shows an un-
usable FLAIR image due to subject movement. Here, time
permitting, radiographers could ask the patient if they feel
able to remain on the table while the scan is repeated. Alter-
natively, the protocol might permit a quick version of the
scan, or use of motion correction with navigator echo
methods, such as such as PROPELLER1 and BLADE.2 Other
motion-correction tools also exist (for example, https://firm-
m.io/). If the problem is not rectified, it can be useful to ap-
pend notes to an affected scan saying so, which prevents
analysts from wasting time looking for better scans that do
not exist. Movement artefacts are a known problem in im-
aging. Those used to working in medical health care rather
than research should note that a subtle movement can affect
automated processing algorithms, even in scans that are
deemed satisfactory from a clinical perspective. Moreover,
good quality scans are much more likely to be usable and
re-usable for many different analyses, years after acquisition.
Figure 4(b) is an example of an image acquired
(wrongly) in the sagittal direction, resulting in unaccept-
able in-plane resolution axially. To maximise information,
it is important to scan the required anatomy fully and to a
consistent standard that permits reproducible analysis.
Figure 4(c) shows the last slice inferiorly from an axially
acquired FLAIR brain scan with insufficient whole brain
coverage, resulting in a large portion of the cerebellar tis-
sue being missing. Not only does this reduce the chance
of capturing all disease, but it means that the brain’s intra-
cranial volume cannot be measured, an important metric
for determining brain shrinkage.
Data quality and completeness should be checked at the
end of the exam before the subject leaves the scanner, and
problems should be rectified, time allowing.
Anonymise, file and folder names, and data upload and
transfer
Data governance regulations require research data to be
anonymised before leaving the health-care system.
Fig. 4 Examples of potentially useless scans: (a) Movement artefact resulting in an unusable scan. (b) MR brain scan with incorrect resolution in
the axial plane (A) due to wrong acquisition plane (B) being used, potentially causing incorrect assessment of pathological features. (c) MR brain
scan with insufficient brain coverage, resulting in a large portion of the cerebellum missed. The last slice was captured inferiorly in the axial plane
(A), with corresponding level on the sagittal reconstruction for reference (B). (d) Incomplete transfer of the entire image acquisition, preventing
complete image reconstruction and any analysis. MR magnetic resonance
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Ethics committees require anonymisation of personally
identifiable information from the raw imaging DICOM
data before it is sent to a central host site for analysis,
particularly if outside the health provider environment.
Participating imaging centres are usually diligent at re-
moving patient names and unique identifiers, but it is
also often important to anonymise sex, age and date of
birth. The trial sponsor, Caldicott Guardian (https://
www.igt.hscic.gov.uk/Caldicott2Principles.aspx) or an-
other data controller may dictate what types of person-
ally identifiable data are permitted in a particular study
and this information should be in the imaging manual
or the study protocol. The process by which
subject-identifiable data are removed from the imaging
dataset header files is important and must not also re-
sult in removal of data essential for subsequent image
analysis. It is possible to recreate facial features, and
hence identify individuals, from structural brain im-
aging data [29]. Consequently, it is recommend to
de-face the images, and there are automated tools for
this purpose (for example, https://surfer.nmr.mgh.har-
vard.edu/fswiki/mri_deface).
In longitudinal studies, it is crucial to be able to dis-
tinguish scans temporally. Thought should be given to
the scan naming convention. The brain imaging data
structure (BIDS) [30] (http://bids.neuroimaging.io/)
recommends use of the “ses” prefix in studies with mul-
tiple time points to denote the session, e.g. “sub-001_-
ses-baseline” would indicate a baseline scan for the first
subject while “sub-001_ses-12 months” would indicate a
12-month follow-up scan. Inclusion of the date in the
scan file name can be helpful. Mixing up baseline and
follow-up scans will lead to incorrect scientific results
and confound the study.
Often in multi-centre imaging studies, a central site
will be the main repository and analysis site. An incom-
plete upload of a source DICOM file from a satellite to
the host site makes it impossible to reconstruct the full
image, as shown in Fig. 4(d). Transfers should be
checked on receipt for completeness as they happen, or
in small batches while it is still possible to repeat the
transfer before the original raw data are wiped from the
scanner or archived by other means. Checking scans on
arrival also allows systematic problems from a particu-
lar site to be identified early and rectified before more
patients are scanned. It is poor practice to verify upload
completeness after the data from many subjects have
been transferred, since it makes the job of rectifying
problems due to poor site performance or scan trans-
fers more cumbersome if not impossible. Consider
manual or automated scan checks. For example, if 60
image slices are expected, did 60 arrive? Regular check-
ing identifies problems early before they multiply
among many cases.
Transfers should be to a resilient and secure server infra-
structure. Cloud-based or drop box methods that are in
common use are unlikely to meet the security requirements.
Quality control
Brain imaging data needs to be processed to provide
meaningful biomedical information. Such processing
can be extensive, and processing pipelines are used to
automate and facilitate this work and should have ro-
bust quality checks at each stage. As well as the exam-
ples in this paper, further examples exist, including
details on what to look for, how to look for them and the
causes (e.g. cbs.fas.harvard.edu/usr/mcmains/CBS_MRI_
Qualitative_Quality_Control_Manual.pdf).
Here we describe the QC checks that should be used
in brain imaging studies to verify accuracy, ordered by
where in the flow of information from scan acquisition
to imaging endpoint they should be conducted:
 Image acquisition – Radiographers should verify
completeness (e.g. whole-brain coverage) and attempt
to rectify movement and other artefacts at the time of
acquisition, per the instructions in the protocol.
 Data upload – The person responsible (a radiographer,
researcher or the data manager) should ensure proper
anonymisation, then transfer the complete exam.
 Data receipt – The receiving centre should check
that all expected images actually arrived.
 Initial QC – After the raw data have been converted
to the processing format (e.g. NIfTI), the analyst
needs to verify that the scans meet the prescribed
quality. For example, was the correct field of view
used? Are there any artefacts? Are any orientations
not flipped? The analyst should also ensure folder
and file naming conventions are consistent and meet
the expectation of the processing pipeline.
 Pre-processing QC – The output should be checked.
For example, did the brain extraction or defacing
method perform adequately? Was there poor image
registration?
 Processing pipeline – Check the compatibility of the
output of each piece of software involved in the
image processing pipeline beforehand on a subset of
representative images from all centres involved.
 Post-processing QC – Check masks and manually
edit them as required. The output files should be
consistently named as per the agreed predefined
conventions (e.g. S001_ses-baseline_acq-
FLAIR_WMHvol).
QC is important as it can affect imaging endpoints,
and hence, has the potential to confound a study. The
Brain Development Cooperative Group reviewed the
development of brain cortical thickness from 5 to 22
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years of age and found that QC procedures had a sig-
nificant impact on the assessment of cortical thickness
developmental trajectories [31]. This finding has impli-
cations for other studies, in for example neurodegener-
ation, where including or excluding scan data based on
how strictly the researcher applies QC procedures
could influence the results. Ioannidis and colleagues
[32] comment that small effects can be difficult to dis-
tinguish from bias and this applies equally to imaging
research and thus, large sample sizes and high-quality
data are critical. Large imaging studies may choose to
use supervised machine learning in the QC pipeline to
identify problematic images (e.g. UK Biobank [17], due
to its sheer size). A visual inspection is usually prefera-
ble in smaller projects, since machine learning methods
require large training sets. Automated and semi-auto-
mated systems for QC exist and should be used. They
can provide a range of useful metrics, such as the
signal-to-noise ratio. Some examples of tools and work-
flows include:
 http://preprocessed-connectomes-project.org/
quality-assessment-protocol/
 https://poldracklab.github.io/mriqc/
 https://raamana.github.io/visualqc/readme.html
Structured data organisation and data sharing
BIDS [30] standardises the approach to describing and
organising neuroimaging data. The use of a structured
approach is critical, not only within a single site (so col-
leagues know what data they are dealing with) but also
across collaborating sites, as it makes pooling data far
simpler as scripts and processing pipelines do not need
to be laboriously re-coded to cater for site-specific nu-
ances. Additionally, the use of this standardised ap-
proach makes it more likely that other researchers will
easily be able to work on the data, and there are an in-
creasing number of software tools being developed that
understand data organised according to BIDS, which
opens the possibility for machine-readable analyses.
Collaborative neuroimaging data management sys-
tems that promote data sharing exist and their use is
encouraged. Consider maximising the benefits of the
research to society by making the data available to
other researchers either through a university’s reposi-
tory facilities or, if available and relevant, by submitting
the data to a brain bank (for example, see the practical
recommendations from the BRAINS Expert Working
Group for enhancing the creation, use and reuse of
neuroimaging data [33]).
Conclusions
Imaging is an evolving science, and metrics derived
from imaging are increasingly being used as study
endpoints. We provide an overview of what is, from ex-
perience, essential for setting up a successful longitu-
dinal or multi-centre imaging study. Following and
implementing these steps will lead to valuable and us-
able data and help avoid wastage of imaging data and
study failure.
1. Plan the study: This includes building relationships
with imaging experts who are best placed to ensure
the study meets its aims.
2. Set up an imaging manual with the essential details
of the imaging process (e.g. include the scanning
protocol and analysis methods). Do this before you
apply for a grant or ethical approval. Implement an
image management system.
3. Perform a dummy run before the trial starts in which
you test your scan protocol on a volunteer and go
through the other imaging procedures needed for
successful study performance. Test your analysis
methods.
4. Carefully acquire scans of high quality that are
consistent across the study.
5. Monitor the scan uploading process and make sure
the scans are received as expected at the central
data site. Decide how to anonymise scans before
transferal to other sites.
6. Implement data QC and quality assurance and
feedback at all appropriate study steps (image
acquisition, data upload, pre-processing and post-
processing) to identify problems early, to give feed-
back to correct problems and thus, to ensure you
have high-quality data.
7. Use structured data and share the data.
Endnotes
1GE (http://www3.gehealthcare.com/en/products/cat-
egories/magnetic_resonance_imaging/mr_applications/
body_imaging/propeller)
2Siemens (https://www.healthcare.siemens.co.uk/mag-
netic-resonance-imaging/options-and-upgrades/clinica-
l-applications/syngo-blade/features-benefits)
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